Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders
An edible wafer containing nutritional supplement formulations suitable for specific enhancement of cell and mitochondrial function comprises enriched formulations of phospholipids or phospholipid chemical precursors containing inulin and specifically identified concentrations of phosphatidylglycerol, phosphatidic acid and phosphatidylcholine, and mitochondrial and cell membrane phospholipid molecules as well as other desirable constituents. These edible wafer lipid combinations can be used to treat mitochondrial disorders associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in many different forms.
1. An edible wafer comprising:
a) a base composition comprising a combination of inulin and phospholipids in therapeutically effective amounts, rosemary extract, pantethine and sodium borate, and
b) a carrier for the base composition comprising xylitol, berry flavor, vegetable stearate, beet juice powder and citric acid,
said wafer effective for maintaining or restoring cell mitochondrial health in a human body, or a specific organ system within a human body, or treating a specific disease or phospholipid deficiency within a human body resulting from a mitochondrial deficiency, wherein the phospholipids in the base composition comprise about 19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%- 10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipids, and phosphatidylserine (PS).
2. The wafer of claim 1 , the wafer being about 0.875 inch in diameter, having a total weight of about 3150 mg, and containing about 1250 mg of the base composition.
3. An edible wafer comprising:
a) a base composition comprising a combination of inulin and phospholipids in therapeutically effective amounts, rosemary extract, pantethine and sodium borate, and
b) a carrier for the base composition comprising xylitol, berry flavor, vegetable stearate, beet juice powder and citric acid,
wherein the phospholipids in the base composition comprise about 29% to about 33% phosphatidylglycerol (PG), about 38% to about 42% phosphatidylcholine (PC), about 24% to about 28% phosphatidylethanolamine (PE), and less than about 5% phosphatidylserine (PS), and optionally further comprise from about 1% to about 5% phosphatidylinositol (PI), said wafer effective for treating phospholipid deficiencies within a human cardiovascular system.
4. An edible wafer comprising:
a) a base composition comprising a combination of inulin and phospholipids in therapeutically effective amounts, rosemary extract, pantethine and sodium borate, and
b) a carrier for the base composition comprising xylitol, berry flavor, vegetable stearate, beet juice powder and citric acid,
wherein the phospholipids in the base composition comprise about 6% to about 39% phosphatidylglycerol (PG), about 29% to about 41% phosphatidylcholine (PC), about 14% to about 42% phosphatidylethanolamine (PE), about 11%-18% phosphatidylserine (PS), and from about 1% to about 5% phosphatidylinositol (PI), said wafer effective for treating phospholipid deficiencies within a human brain.
5. An edible wafer comprising:
a) a base composition comprising a combination of inulin and phospholipids in therapeutically effective amounts, rosemary extract, pantethine and sodium borate, and
b) a carrier for the base composition comprising xylitol, berry flavor, vegetable stearate, beet juice powder and citric acid,
wherein the phospholipids in the base composition comprise about 18% to about 22% phosphatidylglycerol (PG), about 51% to about 55% phosphatidylcholine (PC), about 17% to about 21% phosphatidylethanolamine (PE), about 6%-10% phosphatidylserine (PS), and optionally further comprise from about 1% to about 5% phosphatidylinositol (PI), said wafer effective for treating phospholipid deficiencies within a human respiratory system.
6. An edible wafer comprising:
a) a base composition comprising a combination of inulin and phospholipids in therapeutically effective amounts, rosemary extract, pantethine and sodium borate, and
b) a carrier for the base composition comprising xylitol, berry flavor, vegetable stearate, beet juice powder and citric acid,
wherein the phospholipids in the base composition comprise about 40% to about 44% phosphatidylglycerol (PG), about 31% to about 35% phosphatidylcholine (PC), about 22% to about 26% phosphatidylethanolamine (PE), about 3% phosphatidylserine (PS), and optionally further comprise from about 1% to about 5% phosphatidylinositol (PI), said wafer effective for treating phospholipid deficiencies within human kidneys.
7. An edible wafer comprising:
a) a base composition comprising a combination of inulin and phospholipids in therapeutically effective amounts, rosemary extract, pantethine and sodium borate, and
b) a carrier for the base composition comprising xylitol, berry flavor, vegetable stearate, beet juice powder and citric acid,
wherein the phospholipids in the base composition comprise about 21% to about 25% phosphatidylglycerol (PG), about 46% to about 50% phosphatidylcholine (PC), about 24% to about 28% phosphatidylethanolamine (PE), and less than about 5% phosphatidylserine (PS), and optionally further comprise from about 1% to about 5% phosphatidylinositol (PI), said wafer effective for treating phospholipid deficiencies within a human skeletal system and muscles.
8. An edible wafer comprising:
a) a base composition comprising a combination of inulin and phospholipids in therapeutically effective amounts, rosemary extract, pantethine and sodium borate, and
b)a carrier for the base composition comprising xylitol, berry flavor, vegetable stearate, beet juice powder and citric acid,
wherein the phospholipids in the base composition comprise about 25% to about 29% phosphatidylglycerol (PG), about 68% to about 72% phosphatidylcholine (PC), and less than about 5% phosphatidylethanolamine (PE), and optionally further comprise about 1% to about 5% phosphatidylinositol (PI) and phosphatidylserine (PS), said wafer effective for treating phospholipid deficiencies in human blood plasma.
9. An edible wafer comprising:
a) a base composition comprising a combination of inulin and phospholipids in therapeutically effective amounts, rosemary extract, pantethine and sodium borate, and
b) a carrier for the base composition comprising xylitol, berry flavor, vegetable stearate, beet juice powder and citric acid,
wherein the phospholipids in the base composition comprise about 21% to about 25% phosphatidylglycerol (PG), about 38% to about 42% phosphatidylcholine (PC), about 26% to about 30% phosphatidylethanolamine (PE), and about 7% to about 11% phosphatidylserine (PS), and optionally further comprise about 1% to about 5% phosphatidylinositol (PI), said wafer effective for treating phospholipid deficiencies in human blood platelets.
10. The wafer of claim 3 , the wafer being about 0.875 inch in diameter having a total weight of about 3150 mg and containing about 1250 mg of the base composition.
11. The wafer of claim 4 , the wafer being about 0.875 inch in diameter, having a total weight of about 3150 mg, and containing about 1250 mg of the base composition.
12. The wafer of claim 5 , the wafer being about 0.875 inch in diameter, having a total weight of about 3150 mg, and containing about 1250 mg of the base composition.
13. The wafer of claim 6 , the wafer being about 0.875 inch in diameter, having a total weight of about 3150 mg, and containing about 1250 mg of the base composition.
14. The wafer of claim 7 , the wafer being about 0.875 inch in diameter, having a total weight of about 3150 mg, and containing about 1250 mg of the base composition.
15. The wafer of claim 8 , the wafer being about 0.875 inch in diameter, having a total weight of about 3150 mg, and containing about 1250 mg of the base composition.
16. The wafer of claim 9 , the wafer being about 0.875 inch in diameter, having a total weight of about 3150 mg, and containing about 1250 mg of the base composition.